Clovis Oncology $CLVS slumped 20%�premarket amid heavy volume trading in response to its announcement�of discouraging mid-stage trial data on PARP inhibitor rucaparib in certain patients with treatment-resistant advanced ovarian cancer, an indication that is currently under FDA review (action date is February 23, 2017). The results are being shown at the European Society for Medical Oncology 2016 Congress in Copenhagen.